| INZY Stock | | | USD 2.81 0.12 4.46% |
Inozyme Pharma financial indicator trend analysis is infinitely more than just investigating Inozyme Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Inozyme Pharma is a good investment. Please check the relationship between Inozyme Pharma Current Deferred Revenue and its Accounts Payable accounts. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Inozyme Stock please use our
How to Invest in Inozyme Pharma guide.
Current Deferred Revenue vs Accounts Payable
Current Deferred Revenue vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Inozyme Pharma Current Deferred Revenue account and
Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Inozyme Pharma's Current Deferred Revenue and Accounts Payable is 0.5. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Inozyme Pharma, assuming nothing else is changed. The correlation between historical values of Inozyme Pharma's Current Deferred Revenue and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Inozyme Pharma are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Current Deferred Revenue i.e., Inozyme Pharma's Current Deferred Revenue and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.5 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.
Accounts Payable
An accounting item on the balance sheet that represents Inozyme Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inozyme Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Inozyme Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Inozyme Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
For more information on how to buy Inozyme Stock please use our
How to Invest in Inozyme Pharma guide.
Selling General Administrative is likely to drop to about 14.5
M in 2024.
Issuance Of Capital Stock is likely to drop to about 63.3
M in 2024
Inozyme Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Inozyme Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inozyme Pharma fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to
measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to
predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.